Genelux Corp [GNLX]

Source: 

Company Overview

Genelux is a lateclinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate,Olvi-Vec, is a proprietary, modified strain of the VACV, a stable DNA virus with a large engineering capacity.